2014 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response | De Azambuja E.; Holmes A.P.; Piccart-Gebhart M.; Holmes E.; Di Cosimo S.; Swaby R.F.; Untch M.; Jackisch C.; Lang I.; Smith I.; Boyle F.; Xu B.; Barrios C.H.; Perez E.A.; Azim H.A.; Kim S.-B.; Kuemmel S.; CHIUN-SHENG HUANG ; Vuylsteke P.; Hsieh R.-K.; Gorbunova V.; Eniu A.; Dreosti L.; Tavartkiladze N.; Gelber R.D.; Eidtmann H.; Baselga J. | The Lancet Oncology | 387 | 330 | |